Clinical trial
Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
NCT00216762 · Johns Hopkins University, Other · Terminated
Key facts
| NCT number | NCT00216762 |
|---|---|
| Title | Safety Study of Rituximab (Rituxan®) in Chronic Urticaria |
| Official title | Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - "RUSTY") |
| Lead sponsor | Johns Hopkins University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Urticaria |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 15 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 2, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: